COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.

Phase 1 Completed 121 enrolled Compugen Ltd Bristol-Myers Squibb · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary clinical activity of COM701 as monotherapy and in combination with nivolumab.

Timeline

Start: 2018-09-06
Primary completion: 2024-01-30
Completion: 2024-01-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	COM701	Monoclonal antibody	—	Intravenous
Subject	Nivolumab	Monoclonal antibody	360 mg	Intravenous
Subject	Nivolumab	Monoclonal antibody	480 mg	Intravenous

COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.

Summary

Timeline

Drugs

Indications